N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-2-(3,5-dichlorophenoxy)acetamide

Catalog No. :
ACPZON473
CAS No. :
866154-53-2
Molecular Formula :
C14H15Cl2N3O2S
Molecular Weight :
360.27

IUPAC Name:N-(5-(tert-butyl)-1,3,4-thiadiazol-2-yl)-2-(3,5-dichlorophenoxy)acetamide

N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-2-(3,5-dichlorophenoxy)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$323.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-2-(3,5-dichlorophenoxy)acetamide
IUPAC NameN-(5-(tert-butyl)-1,3,4-thiadiazol-2-yl)-2-(3,5-dichlorophenoxy)acetamide
MDL No.MFCD05669634
Molecular FormulaC14H15Cl2N3O2S
Molecular Weight360.27
SMILESO=C(NC1=NN=C(C(C)(C)C)S1)COC2=CC(Cl)=CC(Cl)=C2
InChI KeyXJMASIDXGDRFMT-UHFFFAOYSA-N
SynonymN-[5-(tert-butyl)-1,3,4-thiadiazol-2-yl]-2-(3,5-dichlorophenoxy)acetamide;Acetamide, 2-(3,5-dichlorophenoxy)-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-
CAS No.866154-53-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACPZON473 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTBRN621 route compound structure diagram
    ACTBRN62139222-73-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPZON473 route product structure diagram
    ACPZON473866154-53-2
Inquiry

2. ACPZON473 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTBRN621 route compound structure diagram
    ACTBRN62139222-73-6 In Stock
  2. Plus
  3. ACVZQE897 route compound structure diagram
    ACVZQE897587-64-4 In Stock
  4. Then
  5. ACPZON473 route product structure diagram
    ACPZON473866154-53-2
Inquiry

Comments (0)